Is A 5% Bitcoin Allocation Wise For Retirement Portfolios?
What's Important For Retirement?
Younger clients with many years to invest can weather the volatility of cryptocurrencies. However, this is not the case for retirees or those approaching retirement. Here are the key considerations for them:
Strategic asset allocation is essential for achieving retirement objectives. We adopt a macro-conscious approach to asset allocation, even within equities – adjusting exposure across sectors and styles in the High Quality Portfolio. Given these objectives – does a volatile and risky asset like Bitcoin fit? As it turns out, it fits remarkably well.
Bitcoin Can Add A Lot Of Return, And Very Little Volatility To A Portfolio
Let's examine a portfolio consisting of 60% equities and 40% bonds – using an S&P 500 index fund and iShares Core U.S. Aggregate Bond ETF (AGG) as examples. We will compare it to a portfolio that allocates 5% of the equity portion to Bitcoin. Additionally, we will analyze both 10-year and 5-year data to determine if there are any changes in characteristics.
The analysis includes two periods: the past 10 years and the past 5 years, to evaluate whether the relationship between risk and return has remained consistent.
Key Findings
The maintenance of a favorable risk-reward ratio over a shorter timeframe of 5 years is promising for retirement accounts – mitigating the risk of liquidation (if necessary) during adverse drawdown scenarios.
Risks
While the data is compelling, there are several risks that investors should consider.
The study on a 5% allocation to Bitcoin illustrates how minor, strategic modifications can enhance portfolio efficiency. The High Quality portfolio adheres to similar principles, outperforming the S&P 500 with over 91% total returns since inception through disciplined asset selection and risk management.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Milestone Scientific Inc (MLSS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Driven ...
Revenue: $2.3 million for Q2 2025, a 25% increase driven by dental segment performance. International Revenue: $1 million for Q2 2025, up from $489,000 in Q2 2024. Medical Revenue: $32,000 for Q2 2025, an increase from $19,000 in Q2 2024. Gross Profit: $1.6 million for Q2 2025, an increase of $206,000 from Q2 2024. Selling, General and Administrative Expenses: $3 million for Q2 2025, up from $2.9 million in Q2 2024. Research and Development Expenses: $52,000 for Q2 2025, down from $352,000 in Q2 2024. Loss from Operations: $1.5 million for Q2 2025, a decrease from $1.8 million in Q2 2024. Cash and Cash Equivalents: $1.3 million as of June 30, 2025. Working Capital: Approximately $3.9 million with no long-term debt. Cash Flows Used in Operating Activities: $2.8 million for the six months ended June 30, 2025. Warning! GuruFocus has detected 6 Warning Signs with MLSS. Release Date: August 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Milestone Scientific Inc (MLSS) reported a 25% revenue growth in Q2 2025, reaching $2.3 million, primarily driven by the dental segment. The company secured Medicare Part B payment rate assignment under CPT code 0770T in multiple jurisdictions, enhancing reimbursement pathways for the CompuFlo Epidural System. International sales more than doubled, contributing significantly to the revenue increase, with international revenue accounting for 48% of total sales. The company has strengthened its leadership team with the appointment of Eric Hines as CEO and Jason Papes as Senior Vice President, Global Head of Sales and Marketing, both bringing extensive experience in scaling operations. Milestone Scientific Inc (MLSS) maintained a solid balance sheet with $1.3 million in cash and no long-term debt, indicating strong financial management. Negative Points Despite the Medicare Part B coverage, adoption of the CompuFlo system in the medical segment has been slow, with only 5 to 10 clinics actively using the product. Domestic dental sales were relatively flat, indicating challenges in growing the US market despite international success. The company reported a loss from operations of approximately $1.5 million for Q2 2025, although this was a decrease from the previous year. Research and development expenses decreased significantly, which could impact future innovation and product development. The company faces challenges with tariffs and international market dynamics, which could affect future growth and profitability. Q & A Highlights Q: Can you discuss the adoption of the CompuFlo system on the medical side, particularly with Medicare Part B coverage, and what steps are being taken to accelerate its adoption? A: Eric Hines, CEO: We currently have between 5 and 10 clinics using the product in the US. The focus is on reimbursement, collecting data, and ensuring doctors are reimbursed appropriately. We plan to invest in specialists to help with claims and data collection, focusing initially on a few clinics to confirm reimbursement processes before expanding further. Q: What are the plans for expanding the sales team under the new Head of Sales, Jason Papes? A: Eric Hines, CEO: Jason brings his prior distribution business, primarily focused in Texas. We are evaluating our current relationships with Axial and Shamrock. The focus will be on US-based sales, particularly in states where we have traction, and potentially hiring additional distribution as needed. Q: What drove the international revenue growth this quarter, and what percentage of total revenue did it represent? A: Keisha Harcum, VP, Finance: International revenue accounted for 48% of total revenue. Growth was driven by additional distributors, larger orders, and improved communication with distributors. The international business tends to be lumpy due to large orders from groups of customers. Q: How are tariffs affecting your international business, and what measures have you taken to mitigate their impact? A: Keisha Harcum, VP, Finance: Tariffs have not significantly impacted us. We have set up direct shipping from our warehouse in China to international partners and have sufficient inventory in the US to avoid tariff-related issues. Q: What is the strategy for expanding reimbursement coverage for the CompuFlo system? A: Eric Hines, CEO: The focus is on deepening relationships in regions with existing reimbursement, collecting data, and ensuring reimbursement processes are solid before expanding. We plan to engage Board members with expertise in reimbursement to assist in this effort. Q: Can you provide an update on the VA status and any progress in that area? A: Eric Hines, CEO: We are focusing on one VA vision in the eastern US to make progress. Each VA operates independently, so the strategy is to succeed in one area first. Neal Goldman, Chairman: Pricing is favorable for both instruments and disposables, and success in the VA could accelerate growth on the medical side. Q: What is the status of the Brazil market, and are there any plans to pursue it further? A: Neal Goldman, Chairman: Brazil remains a long-term potential, but there are no immediate developments due to recent tariffs and other challenges. The focus is on executing in existing markets before expanding to new ones like Brazil. Q: How are clinicians responding to the CompuFlo technology, and is there a plan to leverage their feedback for broader adoption? A: Eric Hines, CEO: We have an advisory group to gather insights from clinicians using the product. The focus is on understanding the pros and cons and collecting data to refine our approach before expanding to a broader market. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
an hour ago
- Yahoo
US Stock market correction 2025: a hidden opportunity to build a £1m ISA?
With the US stock market once again reaching new all-time highs, many portfolios have enjoyed wonderful returns in 2025. Yet, while that's obviously exciting, there's a brewing concern of a potential correction approaching later this year. After all, recent US economic data is starting to look a bit wobbly as the potential impact of tariffs starts to materialise. But could this be a rare opportunity to accelerate the journey towards reaching a £1m investment portfolio? What's going on? Even when stripping out volatile food and energy prices, US inflation's slowly ticking back up. Yet at the same time, the latest revisions to the US jobs report show signs of an economy slowing down. And higher prices combined with slower economic growth are an early indicator of potential stagflation. That puts the Federal Reserve in a pretty sticky situation. Cutting interest rates will cause inflation to rise, while keeping them elevated might cause a further slowdown in economic growth. Pairing this with elevated stock market valuations points towards a looming correction if economic growth doesn't rebound. There's no way of knowing the exact timing of the next stock market correction, but current consensus from analysts at Morgan Stanley suggests it could arrive as early as the third quarter of 2025. Profiting from volatility Stock market corrections are a natural part of every investment journey. And while they can be unpleasant to suffer, they can provide some lucrative buying opportunities for prudent long-term investors, even for typically less volatile enterprises. Take Mastercard (NYSE:MA) as an example. In the 2022 stock market correction, the payment processing giant saw its market-cap shrink by as much as 20%. That's obviously a significant change of pace compared to the stock's typical growth trajectory. However, while most investors were selling off shares, the few that used this volatility to buy at a discount have since gone on to double their money since October 2022. And this perfectly demonstrates how using a market correction can pave the way for impressive market-beating returns for patient long-term investors. Could Mastercard win again? Let's assume the worst, and say that the US stock market takes another tumble on the back of an economic slowdown. Weaker consumer spending will likely translate into lower transaction volumes for Mastercard, likely sparking some selling activity from short-term focused investors. However, as demonstrated countless times before, consumers are relying more and more on debit and credit cards to do their shopping. And that will likely enable transaction volumes to steadily recover alongside the economy. What's more, roughly two-thirds of Mastercard's payment volumes actually come from outside the US, where economic concerns are less prominent. Of course, that doesn't make Mastercard a guaranteed winner. With so much of the global market already under its belt, and tough competition emerging from China, long-term growth expectations are already starting to moderate. And with rising competition from novel fintech payment solutions, the group's duopoly with Visa could already be getting attacked. Nevertheless, management isn't blind to these risks. And with an impressive track record of navigating through economic storms, as well as fending off potential disruptors, Mastercard shares could still be worth a closer look if the US stock market indeed decides to throw a tantrum in the future. The post US Stock market correction 2025: a hidden opportunity to build a £1m ISA? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Zaven Boyrazian has positions in Mastercard. The Motley Fool UK has recommended Mastercard. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
We Think You Should Be Aware Of Some Concerning Factors In Fabasoft's (ETR:FAA) Earnings
Explore Fabasoft's Fair Values from the Community and select yours Fabasoft AG's (ETR:FAA ) stock didn't jump after it announced some healthy earnings. Our analysis showed that there are some concerning factors in the earnings that investors may be cautious of. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. A Closer Look At Fabasoft's Earnings In high finance, the key ratio used to measure how well a company converts reported profits into free cash flow (FCF) is the accrual ratio (from cashflow). In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. The ratio shows us how much a company's profit exceeds its FCF. That means a negative accrual ratio is a good thing, because it shows that the company is bringing in more free cash flow than its profit would suggest. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking. For the year to June 2025, Fabasoft had an accrual ratio of 0.28. Therefore, we know that it's free cashflow was significantly lower than its statutory profit, which is hardly a good thing. To wit, it produced free cash flow of €5.8m during the period, falling well short of its reported profit of €9.21m. Fabasoft shareholders will no doubt be hoping that its free cash flow bounces back next year, since it was down over the last twelve months. Having said that, there is more to the story. The accrual ratio is reflecting the impact of unusual items on statutory profit, at least in part. See our latest analysis for Fabasoft That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. The Impact Of Unusual Items On Profit Unfortunately (in the short term) Fabasoft saw its profit reduced by unusual items worth €2.4m. In the case where this was a non-cash charge it would have made it easier to have high cash conversion, so it's surprising that the accrual ratio tells a different story. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. If Fabasoft doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year. Our Take On Fabasoft's Profit Performance Fabasoft saw unusual items weigh on its profit, which should have made it easier to show high cash conversion, which it did not do, according to its accrual ratio. Having considered these factors, we don't think Fabasoft's statutory profits give an overly harsh view of the business. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. For example - Fabasoft has 1 warning sign we think you should be aware of. Our examination of Fabasoft has focussed on certain factors that can make its earnings look better than they are. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
